Hold MDLZ with $60.50 stop; await breakout confirmation above $64.74 before scaling
Maintain MDLZ as defensive ballast with disciplined stop at $60.50 (hard stop at $58.56); structural thesis justifies continued ownership but tactical uncertainty (failed $64.74 breakout, negative MACD for 18 sessions, relative underperformance) warrants HOLD rather than adding. NaN-alpha track record on prior MDLZ decisions and confirmed -0.5% return on Sept 14 Underweight call validate that directional conviction on quality compounders with defended floors generates structurally capped negative alpha. Core position discipline is HOLD with stop; if scaling, use neutral analyst's tranche framework (25% on 50 SMA retest, 25% on breakout, 50% reserve) only after confirmation triggers fire.
| Position | Action |
|---|---|
| Clean 50 SMA retest at $61.70-$61.74 with bullish reversal candle | Add 25% starter tranche (if scaling desired) |
| Breakout confirmation (close >$64.74 on volume ≥10M with MACD histogram positive) | Add additional 25% |
| Reserve capital | Hold 50% in reserve for subsequent confirmation or defensive repositioning |
MDLZ is a defensive CPG powerhouse with margin recovery already underway, an iconic brand (Oreo) reinvestment cycle launching in 2027, and a technical coil positioned for directional upside — trading at a sub-1.0 PEG ratio that the market has not fully priced in.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 51.05 | neutral |
| MACD Histogram | -0.106 | bearish |
| 10 EMA | 62.25 | neutral |
| 50 SMA | 61.74 | bullish |
| 200 SMA | 58.59 | bullish |
| Bollinger Upper | 64.74 | bearish |
| Bollinger Middle (20 SMA) | 62.73 | neutral |
| Bollinger Lower | 60.71 | bullish |
| ATR (14) | 1.27 | neutral |
| Bollinger Band Width | 4.03 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Clean retest of 50 SMA at $61.70-$61.74 with bullish reversal candle
Then: Alternative entry for 25% starter tranche if scaling
↩ rebuts: “European packaging costs and brand weakness”
EV: $66.65 (Target #1: prior high retest); $68.00+ (Target #2: measured move on breakout)
MDLZ is a defensive trap disguised as opportunity—the margin recovery is fragile and dependent on cocoa normalization that has not been proven durable, the technical setup is a coiled trap with intact resistance and deteriorating momentum, and the balance sheet is leveraged with capital returns funded 150% by FCF, creating asymmetric downside risk of approximately 2.6:1.
· concedes: MDLZ is not going to zero—it's a $79B market-cap defensive name; The margin recovery is real, just fragile and not yet proven sustainable; The Oreo 2027 relaunch strategy exists; Dividend yield provides some income floor; Bollinger lower band at $60.71 has been respected three times; Some institutional tape is mildly positive (6.2/10 sentiment); Beta of 0.40 does provide some downside protection in market selloffs
→ vs conservative: Conservative's $64.74 resistance framing is statistically weak; each failed test consumes supply with sellers absorbed at higher levels, and four tests in a tightening range means level is closer to giving way
→ vs conservative: Capital returns exceeding FCF ($4.87B vs $3.24B) reflects shareholder-friendly capital allocation priority for mature low-beta business, not financial weakness; net debt still declined from $21.01B to $19.08B over four years
→ vs conservative: MDLZ 2.8% return vs S&P 12.1% over six months is expected defensive behavior during risk-on rallies; underperformance is the entry signal for rotation trade as recession odds rise
→ vs conservative: Conservative is ignoring the Oreo 2027 relaunch of five-billion-dollar brand (~13% of revenue) with multi-quarter revenue acceleration potential, underpricing forward earnings power
→ vs neutral: MACD bearish interpretation is a mistake; histogram flattening from -0.31 to -0.11 is textbook positive crossover setup within next few sessions; RSI 51 is neutral, not bearish
→ vs neutral: Wait-for-confirmation framing misprices structural setup; 3.33% growing dividend yield with 13.34% ROE and sub-1.0 PEG makes this an attractive risk-adjusted position even if stock chops sideways another quarter
→ vs neutral: The HOLD is not a 'wait and see' placeholder; it's an offensive position maintaining exposure to coiled volatility resolution, 3.33% yield, and brand relaunch optionality
| Golden Cross (50 SMA vs 200 SMA) |
| 3.15 spread |
| bullish |
Support: 60.71 · 58.59 | Resistance: 64.74 · 66.65
The technical setup shows a structural bull trend intact with both the 50 SMA ($61.74) and 200 SMA ($58.59) rising, and price sitting 6.6% above the 200 SMA. Short-term momentum is neutral-to-bearish with RSI at 51.05 and MACD histogram negative at -0.106, having turned negative on 8/17. Volatility is contracting with Bollinger band width at $4.03 and ATR at $1.27 (down ~30% from August peak of ~$1.80), creating a coiled setup. Price is consolidating between the Bollinger lower ($60.71, tested and bounced 3×) and upper ($64.74, rejected 4×), with the 10 EMA ($62.25) acting as immediate pivot. Two major volume spikes occurred: 25.6M shares on 6/18 (capitulation low $57.84) and 20.2M shares on 7/29 (intraday high $66.65). The overall bias is bullish long-term but neutral-tactical short-term pending a breakout catalyst.
Market Cap
$79.26 Billion
Revenue (TTM)
$39.67B
Revenue (FY2025)
$38.54B
Revenue (FY2024)
$36.44B
Revenue (FY2023)
$36.02B
Revenue (FY2022)
$31.50B
Gross Profit (TTM)
$12.36B
Gross Profit (FY2025)
$10.94B
Gross Margin (FY2025)
28.4%
Gross Margin (FY2024)
39.1%
EBITDA (TTM)
$6.08B
EBITDA (FY2025)
$4.97B
Net Income (TTM)
$3.52B
Net Income (FY2025)
$2.45B
Net Income (FY2024)
$4.61B
EPS (TTM)
$2.73
EPS (FY2025)
$1.89
Forward EPS
$3.36
Operating Margin (TTM)
21.98%
Operating Margin (FY2025)
9.4%
Profit Margin (TTM)
8.86%
ROE
13.34%
Free Cash Flow (TTM)
$2.25B
Free Cash Flow (FY2025)
$3.24B
Free Cash Flow (FY2024)
$3.52B
Free Cash Flow (FY2023)
$3.60B
Total Debt
$21.80B
Net Debt
$19.08B
Cash & Equivalents
$2.13B
Debt/Equity
82.6%
Current Ratio
0.60
Book Value/Share
$20.80
PE Ratio (TTM)
22.75x
Forward PE
18.47x
PEG Ratio
0.92
Price/Book
2.99x
Dividend Yield
3.33%
Total Capital Return (FY25)
$4.87B
Dividends Paid (FY25)
$2.49B
Buybacks (FY25)
$2.39B
CapEx (FY25)
$1.28B
Beta
0.40
52-Week High
$66.65
52-Week Low
$51.20
50-Day Moving Avg
$61.77
200-Day Moving Avg
$59.25
Goodwill & Intangibles
$43.96B
Strengths
Concerns
Mondelez International delivered FY2025 revenue of $38.54B (up 5.8% YoY) but suffered severe earnings compression with net income plummeting 47% to $2.45B and operating margin collapsing to 9.4% as cocoa and dairy costs surged, resulting in a 10.7 percentage point gross margin decline. However, TTM metrics reveal a strong recovery underway with operating margin rebounding to 22.0% and net income recovering to $3.52B, signaling the commodity headwinds are normalizing. The company maintains a robust free cash flow profile ($3.24B in FY2025), a 3.33% dividend yield, and trades at a forward PE of 18.47x with a PEG ratio of 0.92, offering an attractive risk-adjusted profile as a defensive consumer staples holding with margin recovery tailwinds.